IDH2 R140Q in DLBCL is exceptional (<1%). No targeted therapy in this indication; per usu...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH2-R140Q-DLBCL-NOS |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-DLBCL-NOS |
| Sources | SRC-CIVIC SRC-NCCN-BCELL-2025 |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH2 R140Q |
| Disease | DIS-DLBCL-NOS |
| ESCAT tier | IV |
| Evidence summary | IDH2 R140Q in DLBCL is exceptional (<1%). No targeted therapy in this indication; per usual DLBCL algorithm. |
Notes
ESCAT IV.
Used By
No reverse references found in the YAML corpus.